Home Clinical Trials Update

Clinical Trials Update

Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Trastuzumab Duocarmazine Selected to be part of a New Investigational Treatment Arm for the...

The Quantum Leap Healthcare Collaborative™, a 501c(3) charitable organization established as a collaboration between medical researchers at University of...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent...
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

Positive Phase II Trial Results for Tisotumab Vedotin Cervical Cancer

The phase II innovaTV 204 trial, a single-arm clinical trial also known as GCT1015-04 or GOG-3023/ENGOT-cx6 (NCT03438396), evaluating tisotumab...

AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial

Maturing data from the pivotal Phase II LOTIS 2 study (NCT04384484), a clinical trial of loncastuximab tesirine (formerly ADCT-402)...
Photo: AbbVie R&D has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology. Photo courtesy: © 2019 - 2020 AbbVie

Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid...

Research linked to the development of Antibody-drug Conjugates (ADC) for the treatment of human diseases has, for decades, been...

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits...
Featured Image: Better times - ASCO | McCormick Place. Courtesy: © 2017 Fotolia. Used with permission.

ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent Ovarian Cancer

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853),...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Sorrento Confirms FDA IND Clearance to Initiate a Phase I Clinical Trial of STI-6129...

Sorrento Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start phase I clinical trials...